Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.

Danaher Corporation

In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Danaher, with a price target of $270.00. Rysk...

Bank of America Securities Reaffirms Their Buy Rating on Danaher (DHR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lipocine (LPCN), Amylyx Pharmaceuticals Inc (AMLX) a...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Insiders have been trading these 5 stocks: (($DHR)), (($CIFR)), (($EQIX)), (($MTCH)) and (($CLX)). Here is a breakdown of their recent trades and t...

Danaher, Cipher, Equinix, Match, Clorox: Insider Shake-Up

The latest update is out from B&G Foods ( ($BGS) ). B&G Foods disclosed leadership changes affecting key business units, with Executive Vice Presid...

B&G Foods Announces Executive Departures and Interim Leadership Shift

Danaher ( ($DHR) ) has shared an update. On April 29, 2026, Danaher issued €3 billion in euro-denominated senior notes across four tranches, includ...

Current Quarter	$1.85	Next Quarter	$2.04
Current Year	$8.43	Next Year	$9.11
QoQ Growth	+10.3%	YoY Growth	+8.1%
3Y EPS CAGR	-33.7%	Target Price	$243.20
Consensus	Buy	Upside	+40.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DHR	$172.81	+0.47%	3.28M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DHR	$172.81	+0.5%	3.28M
3
4
5
6

DHR

DHR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Danaher Corporation Data in Excel

Get Danaher Corporation Data in Excel